Please login to the form below

Not currently logged in
Email:
Password:

Zostavax

This page shows the latest Zostavax news and features for those working in and with pharma, biotech and healthcare.

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

CDC backs GSK’ s Shingrix over Merck &Co’ s Zostavax. US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product. ... Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors

Latest news

  • GSK’s shingles vaccine Shingrix claims US approval GSK’s shingles vaccine Shingrix claims US approval

    GSK’ s shingles vaccine Shingrix claims US approval. Becomes first alternative to Merck &Co’s Zostavax. ... The FDA has approved Shingrix for the prevention of shingles in adults aged 50 years and older, and it becomes the first alternative to Merck

  • GSK's Shingrix sails through FDA advisory committee GSK's Shingrix sails through FDA advisory committee

    It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial

  • GSK makes case for revaccination with Shingrix GSK makes case for revaccination with Shingrix

    The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy

  • GSK files shingles vaccine Shingrix in Europe GSK files shingles vaccine Shingrix in Europe

    GSK files shingles vaccine Shingrix in Europe. Blockbuster hopeful would compete with Merck &Co’ s Zostavax. ... By contrast, Zostavax - currently the only shingles vaccine on the market - has an efficacy of between 18% and 70% and is both less

  • GSK's blockbuster hopeful Shingrix filed in US GSK's blockbuster hopeful Shingrix filed in US

    In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics